Plasma Homocysteine and l-DOPA Metabolism in Patients with Parkinson Disease

Authors:

Abstract
Homocysteine is formed by demethylation of methionine and is involved in transmethylation mechanisms. Hyperhomocysteinemia is associated with a wide range of clinical manifestations, mostly affecting the central nervous system (e.g., mental retardation, cerebral atrophy, and epileptic seizures) (1)(2). Hyperhomocysteinemia has also been associated with an increased risk for atherosclerotic and thrombotic vascular diseases (3)(4)(5). Although various mechanisms have been proposed, mostly involving endothelial damage related to increased oxidative stress (6), the exact cellular and molecular bases for the adverse effects of homocysteine are still elusive.